Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ELVN
ELVN | US
29.73
USD0.29
0.99%
ELVN | US
Loading StockChartView...
About ELVN
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
29.73
Open
28.88
High
30.30
Low
27.81
Enliven Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001 which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002 a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder Colorado.
View LessELVN | US
Risk
40.6
Sharpe
0.40
Luna's Score
51/100
Recommendation
Hold
Luna says (ELVN | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
41.3%1 month
40.6%3 months
118.9%6 months
94.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.49
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-6.28
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-95.95M
MarketCap
1.40B
MarketCap(USD)
1.40B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-28.37
Short ratio
26.76
Short perc.
31.97
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
4.84
Range1M
5.34
Range3M
15.85
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.87
Price X volume
17.09M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -6.28 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.49 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 118.88 | 72.80 | Riskier |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 1.40B | 3.66B | Emerging |
